Reporte zur Charge GJ33275

Symptomtext

Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient. A 76-year-old patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 25Nov2022 at 12:00 as dose 5 (booster), single (Lot number: GJ33275) at the age of 76 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 26Jan2021 at 12:00 as dose 1, single (Lot number: EL9262), in left arm, on 14Feb2021 at 12:00 as dose 2, single (Lot number: EL9269), in left arm, on 11Oct2021 at 12:00 as dose 3 (booster), single (Lot number: FF2587), in left arm and on 22Aug2022 at 12:15 as dose 4 (booster), single (Lot number: FP7138), in left arm for covid-19 immunisation. The patient's relevant medical history included: "HighBP" (unspecified if ongoing); "low Thyroid" (unspecified if ongoing), notes: low Thyroid; "gERD" (unspecified if ongoing). The patient took concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment; Negative, notes: Rebound Covid 3 days after testing negative. Therapeutic measures were taken as a result of vaccination failure, covid-19.